Table 1 Summary of MC38, Hepa1–6, CT26 and EMT-6 subcutaneous tumor growth inhibition and % immune cell depletion following treatment for lineage specific depletion either alone (% relative to non-treated control, experiment 1) or in combination with anti-PD-1 antibody treatment (% relative to anti-PD-1 control, experiment 2).

Experiment 1	MC38		Hepa1-6		CT26		EMT6
Treatment	TGI	% Depletion compared to untreated vehicle	TGI	% Depletion compared to untreated vehicle	TGI	% Depletion compared to untreated vehicle	TGI	% Depletion compared to untreated vehicle
Anti-PD1	65%	–	58%	–	33%	–	48%	–
Anti-CD8	− 12%	− 98%	12%	− 99%	− 9%	− 97%	− 31%	− 100%
Anti-CD4	22%	− 100%	− 122%	− 100%	− 12%	− 100%	55%	− 100%
Anti-NK	13%	− 91%	18%	− 62%	− 17%	− 67%	− 35%	− 67%
MØ depletion (clodronate liposomes)	39%	− 32%	25%	13%	27%	12%	56%	− 71%
Anti-CD25	42%	3%	− 1%	− 6%	54%	23%	50%	189%

Experiment 2	MC38			Hepa1-6			CT26			EMT6
Treatment	TGI compared with vehicle	TGI compared with PD-1	% Depletion compared to anti-PD-1	TGI compared with vehicle	TGI compared with PD-1	% Depletion compared to anti-PD-1	TGI compared with vehicle	TGI compared with PD-1	% Depletion compared to anti-PD-1	TGI compared with vehicle	TGI compared with PD-1	% Depletion compared to anti-PD-1
anti-PD-1	45%			69%			53%			65%
anti-PD-1/anti-CD8	− 1%	− 83%	− 99%	43%	− 87%	− 98%	− 78%	− 205%	− 95%	− 121%	− 461%	− 93%
Anti-PD-1/anti-CD4	82%	67%	− 99%	− 101%	− 557%	− 100%	46%	− 35%	− 99%	81%	− 147%	− 58%
anti-PD-1/anti-NK	51%	11%	− 70%	47%	− 72%	− 81%	14%	− 46%	− 39%	51%	− 62%	− 2%
Anti-PD-1/MØ-depletion	84%	72%	− 18%	46%	− 76%	64%	76%	54%	3%	75%	29%	− 71%
anti-PD-1/anti-CD25	90%	71%	− 11%	68%	− 6%	100%	94%	82%	− 14%	92%	78%	321%

Experiment 3	MC38
Treatment	TGI	% Depletion compared to untreated
DTR-KI-CD8	− 259%	− 98
DTR-KI-CD4	61%	− 79
DTR-KI-FoxP3	94%	− 74%
DTR-KI-NCR1	− 33%	− 53

Search